Target intelligence / Profile preview

Human immunodeficiency virus type 1 group-specific antigen protein p24 (p24)

Target
p24
Molecular classification
Structural protein, Viral capsid protein, Other (not a receptor, enzyme, transporter, transcription factor, etc.), Family: Retroviral Gag polyprotein components
01

Overview

The p24 protein of Human immunodeficiency virus type 1 is the major structural component of the viral capsid, forming a cone-shaped shell around the viral RNA genome. Encoded by the gag gene, p24 is composed of N-terminal and C-terminal domains linked flexibly and exists as pentamers or hexamers in assembled virions. Its structure has been extensively studied by X-ray crystallography and cryo-electron microscopy, revealing interactions between host factors such as cyclophilin A and regions critical for capsid morphology and infectivity. Though not considered a classical therapeutic target (such as enzymes or receptors), p24 is a promising focus for antiviral research due to its essential role in capsid assembly and viral replication. It is widely used as a diagnostic biomarker in early HIV infection and remains an important research subject for understanding virus-host interactions, capsid dynamics, and potential antiviral strategies.

Other names
HIV-1 capsid proteinHIV-1 CA proteinGroup-specific antigen protein p24p24 capsid protein
02

Mechanism of action

Capsid destabilization or stabilization: Small molecules (e.g., PF74) bind to pockets within hexameric p24 and interfere with capsid integrity and virus replication

03

Biological functions

Capsid formation (forms the cone-shaped shell enclosing HIV RNA)Structural stability of viral particlesFacilitates viral assembly and morphogenesisSupports entry and release of virions from host cellsInteraction with host proteins (e.g., cyclophilin A) for infectivity
04

Disease associations

Infection (central to Human immunodeficiency virus type 1/AIDS)Biomarker for HIV diagnosis
05

Safety considerations

Antigen clearance: p24 is generally cleared from the bloodstream after acute infection, limiting its use as a long-term biomarkerHigh mutation rate: Genetic diversity across HIV variants affects p24’s structure and may impact drug or antibody bindingImmunogenicity: As a viral protein, immune system targeting can lead to escape mutants or variable efficacy
06

Interacting drugs

PF74
07

Biomarkers

p24 antigen (used in HIV diagnostic assays and early detection before antibody response develops)

Beyond the preview

Go deeper on Human immunodeficiency virus type 1 group-specific antigen protein p24 (p24).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human immunodeficiency virus type 1 group-specific antigen protein p24 (p24).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call